Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$3.80 USD
-0.02 (-0.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.80 USD
-0.02 (-0.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
by Zacks Equity Research
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Cigna Group (CI) This Year?
by Zacks Equity Research
Here is how Cigna (CI) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 8th
by Zacks Equity Research
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
5 Small-Cap Stocks to Play the January Effect
by Sweta Killa
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
New Strong Buy Stocks for January 8th
by Zacks Equity Research
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 13.16% and 5.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -15.91% and 6.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
by Zacks Equity Research
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -61.82% and 9.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.
Kodiak (KOD) Down as Late-Stage DME Studies Fail
by Zacks Equity Research
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.
Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use
by Zacks Equity Research
Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.